Document:

Exhibit 10.1 to CNS, Inc. Form 8-K dated May 1, 2006

Exhibit 10.1 

 

CNS, INC.

 

1989 EMPLOYEE STOCK PURCHASE PLAN

 

As Amended Effective July 1, 1999 and July 1, 2006

 

	
            1.
 	
            Establishment of Plan.   CNS, Inc. (hereinafter referred to as the “Company”) proposes to grant to certain employees of the Company the opportunity to purchase common stock of the Company. Such common stock shall be purchased pursuant to the plan herein set forth, which shall be known as the “CNS 1989 EMPLOYEE STOCK PURCHASE PLAN” (hereinafter referred to as the “Plan”). The Company intends that the Plan shall qualify as an “Employee Stock Purchase Plan” under Section 423 of the Internal Revenue Code of 1986, as amended, and shall be construed in a manner consistent with the requirements of said Section 423 and the regulations thereunder.
 

 

	
            2.
 	
            Purpose.   The Plan is intended to encourage stock ownership by all employees of the Company, and as an incentive to them to remain in employment, improve operations, increase profits, and contribute more significantly to the Company’s success.
 

 

	
            3.
 	
            Administration.   The Plan shall be administered by the Compensation Committee of the Board of Directors (hereinafter referred to as the “Committee”) or in the absence of such Committee, a committee designated by the Board of Directors of the Company (hereinafter referred to as the “Board of Directors”). The Board of Directors shall fill all vacancies in the Committee and may remove any member of the Committee at any time, with or without cause. The Committee shall select its own chairman and hold its meetings at such times and places as it may determine. All determinations of the Committee shall be made by a majority of its members. Any decision that is made in writing and signed by a majority of the members of the Committee shall be effective as fully as though made by a majority vote at a meeting duly called and
held. The determinations of the Committee shall be made in accordance with its judgment as to the best interests of the Company, its employees and its shareholders and in accordance with the purposes of the Plan; provided, however, that the provisions of the Plan shall be construed in a manner consistent with the requirements of Section 423 of the Internal Revenue Code, as amended. Such determination shall be binding upon the Company and the participants in the Plan unless otherwise determined by the Board of Directors. The Company shall pay all expenses of administering the Plan. No member of the Board of Directors or the Committee shall be liable for any action or determination made in good faith with respect to the Plan or any option granted under it.
 

 

	
            4.
 	
            Duration and Phases of the Plan.
 

 

	
             
 	
            a)
 	
            The Plan was originally effective and commenced on July 1, 1989; effective as of July 1, 1999 the Plan is extended and will thereafter terminate July 1, 2009, except that any phase commenced prior to such termination shall, if necessary, be allowed to continue beyond such termination until completion. Notwithstanding the foregoing, this Plan shall be considered of no force or effect and any options granted shall be considered null and void unless the holders of a majority of all of the issued and outstanding shares of the common stock of the Company approve the Plan within twelve (12) months before or after the date of its adoption by the board of Directors.
 

 

	
             
 	
            b)
 	
            The Plan shall be carried out in one or more phases, each phase being for a period of six months. No phase shall run concurrently, but a phase may commence immediately after the termination of the preceding phase. The existence and date of commencement of a phase (the “Commencement Date”) shall be determined by the Committee, provided that the commencement of the first phase shall be within twelve (12) months before or after the date of approval of the Plan by the shareholders of the Company. In the event all of the stock reserved for grant of options hereunder is issued pursuant to the terms hereof prior to the commencement of one or more phases scheduled by the Committee or the number of shares remaining is so small, in the opinion of the Committee, as to render administration of any succeeding phase impracticable, such phase or phases shall be
cancelled. Phases shall be numbered successively Phase 1, Phase 2, Phase 3, etc.
 

 

	
            5.
 	
            Eligibility.   All Employees who are employed by the Company on the Commencement Date of a phase shall be eligible to participate in such phase. For purposes of this Plan, effective July 1, 2006, “Employee” shall mean any employee, including an officer, of the Company who as of the Commencement Date of a phase is customarily employed by the Company for more than twenty (20) hours per week and more than five (5) months per year.
 

 

	
            6.
 	
            
Participation.   Participation in the Plan
is voluntary. An eligible Employee may elect to participate in any phase of the
Plan, and thereby become a “Participant” in the Plan, by completing
the Plan payroll deduction form provided by the Company and delivering it to the
Company or its designated representative prior to the Commencement Date or that
phase. Payroll deductions for a Participant shall commence on the first payday
after the Commencement Date of the phase and shall terminate on the last payday
immediately prior to or coinciding with the termination date of that phase
unless sooner terminated by the Participant as provided in Paragraph 9
hereof.

 

	
            7.
 	
            Payroll Deductions. 
 

 

	
             
 	
            a)
 	
            Upon enrollment, a Participant shall elect to make contributions to the Plan by payroll deductions (in amounts calculated to be as uniform as practicable throughout the period of the phase), in the aggregate amount not in excess of 10% of such Participant’s Base Pay for the term of the phase. For purposes of this Plan, “Base Pay” is the regular pay for employment for each employee as annualized for a twelve (12) month period, exclusive of overtime, commissions, bonuses, disability payments, shift differentials, incentives and other similar payments, determined as of the Commencement Date of each phase. The minimum authorized payroll deduction must aggregate at least $10 per month.
 

 

	
             
 	
            b)
 	
            In the event that the Participant’s compensation for any pay period is terminated or reduced from the compensation rate for such a period as of the Commencement Date of the phase for any reason so that the amount actually withheld on behalf of the Participant as of the termination date of the phase is less than the amount anticipated to be withheld over the phase year as determined on the Commencement Date of the phase, then the extent to which the participant may exercise his or her option shall be based on the amount actually withheld on his or her behalf. In the event of a change in the pay period of any Participant, such as from bi-weekly to monthly, an appropriate adjustment shall be made to the deduction in each new pay period so as to ensure the deduction of the proper amount authorized by the Participant.
 

 

	
             
 	
            c)
 	
            All payroll deductions made for Participants shall be credited to their accounts under the Plan. The Participant may not make any separate cash payments into such account.
 

 

	
             
 	
            d)
 	
            Except for his or her right to discontinue participation in the Plans as provided in Paragraph 9, no Participant shall be entitled to increase or decrease the amount to be deducted in a given phase after the Commencement Date.
 

 

	
            8.
 	
            Options.
 

 

	
             
 	
            a)
 	
            Grant of Option.
 

 

	
             
 	
            i)
 	
            A Participant who is employed by the Company as of the Commencement Date of a phase shall be granted an option as of such date to purchase a number of full shares of Company common stock to be determined by dividing the total amount to be credited to that Participant’s account under Paragraph 7 hereof by the option price set forth in Paragraph 8(a)(ii) hereof (not to exceed 15,000 shares per Participant), subject to the limitations of Paragraph 10 hereof.
 

 

	
             
 	
            ii)
 	
            The option price for such shares of common stock shall be the lower of:
 

 

	
             
 	
            A.
 	
            Eighty-five percent (85%) of the fair market value of such shares of common stock on the Commencement Date of the phase; or
 

 

	
             
 	
            B.
 	
            Eighty-five percent (85%) of the fair market value of such shares of common stock on the termination date of the phase.
 

 

	
             
 	
            iii)
 	
            The fair market value of shares of common stock of the Company shall be determined by the Committee for each valuation date in a manner acceptable under Section 423, Internal Revenue Code of 1986, as amended.
 

 

	
             
 	
            iv)
 	
            Anything herein to the contrary notwithstanding, no Employee shall be granted an option hereunder:
 

 

	
             
 	
            A.
 	
            Which permits his or her rights to purchase stock under all employee stock purchase plans of the Company, its subsidiaries or its parent, if any, to accrue at a rate which exceeds Twenty-Five Thousand Dollars ($25,000) of the fair market value of such stock (determined at the time such option is granted) for each calendar year in which such option is outstanding at any time;
 

 

2

	
             
 	
            B.
 	
            
If immediately after the grant such Employee would own and/or hold
outstanding options to purchase stock possessing five percent (5%) or more of
the total combined voting power or value of all classes of stock of the Company,
its parent, if any, or of any subsidiary of the Company. For purposes of
determining stock ownership under this Paragraph, the rules of Section 425(d) of
the Internal Revenue Code of 1986, as amended, shall apply; or
 

 

	
             
 	
            C.
 	
            Which can be exercised after the expiration of 27 months from the date the option is granted.
 

 

	
             
 	
            b)
 	
            Exercise of Option.
 

 

	
             
 	
            i)
 	
            Unless a Participant gives written notice to the Company pursuant to Paragraph 9 prior to the termination date of a phase, his or her option for the purchase of shares will be exercised automatically as of such termination date for the purchase of the number of full shares of Company common stock which the accumulated payroll deductions in his or her account at that time will purchase at the applicable option price, subject to the limitations set forth in Paragraph 10 hereof.
 

 

	
             
 	
            ii)
 	
            As promptly as practicable after the termination date of any phase, the Company will deliver to each Participation herein the common stock purchase upon the exercise of his or her option, together with a cash payment equal to the balance, if any, of his or her account which was not used for the purchase of common stock without interest thereon.
 

 

	
            9.
 	
            Withdrawal or Termination of Participation. 
 

 

	
             
 	
            a)
 	
            A Participant may, at any time prior to the termination date of a phase, withdraw all payroll deductions then credited to his or her account by giving written notice to the Company. Promptly upon receipt of such notice of withdrawal, all payroll deductions credited to the Participant’s account will be paid to him or her without interest thereon and no further payroll deductions will be made during that phase. In such event, the option granted the Participant under that phase of the Plan shall lapse immediately. Partial withdrawals of payroll deductions hereunder may not be made.
 

 

	
             
 	
            b)
 	
            Effective beginning July 1, 2006, in the event the Participant’s participation is suspended under the CNS, Inc. Employees’ 401(k) Plan and Trust as a result of receiving a hardship withdrawal, the Participant shall be immediately and automatically suspended from the Plan, in which case the provisions of Section 9(a) shall apply. The Participant may again participate in the Plan as of the Commencement Date of the first Phase that begins no earlier than six months after the date of the hardship withdrawal.
 

 

	
             
 	
            c)
 	
            In the event of the death of a Participant, the person or persons specified in Paragraph 14 may give notice to the Company within sixty (60) days of the death of the Participant electing to purchase the number of full shares which the accumulated payroll deductions in the account of such deceased Participant will purchase at the option price specified in Paragraph 8(a)(ii) and have the balance in the account distributed in cash without interest thereon. If no such notice is received by the Company within said sixty (60) days, the accumulated payroll deductions will be distributed in full in cash without interest thereon.
 

 

	
            10.
 	
            Stock Reserved for Options.
 

 

	
             
 	
            a)
 	
            As of July 1, 1989, one hundred thousand (100,000) shares of the Company’s no par value common stock which may be authorized by unissued or treasury shares of the Company (or the number and kind of securities to which said one hundred thousand (100,000) shares may be adjusted in accordance with Paragraph 12 hereof) are reserved for issuance upon the exercise of options to be granted under the Plan. Shares subject to the unexercised portion of any lapsed or expired option may again be subject to option under the Plan.
 

 

	
             
 	
            b)
 	
            If the total number of shares of Company common stock for which options are to be granted for a given phase as specified in Paragraph 8 exceeds the number of shares then remaining available under the Plan (after deductions of all shares for which options have been exercised or are then outstanding) and if the Committee does not elect to cancel such phase pursuant to Paragraph 4, the Committee shall make a pro rata allocation of the shares remaining available in as uniform and equitable a manner as it shall consider practicable. In such event, the options to be granted and the payroll deductions to be made pursuant to the Plan, which would otherwise be effected, may, in the discretion of the Committee, be reduced accordingly. The Committee shall give written notice of such reduction to each Participant affected.
 

3

	
             
 	
            c)
 	
            
The Participant and a joint tenant named pursuant to Paragraph
10(d) hereof shall have no rights as a shareholder with respect to any shares
subject to the Participant’s option until the date of the issuance of a
stock certificate evidencing such shares. No adjustment shall be made for
dividends (ordinary or extraordinary, whether in cash, securities or other
property), distributions or other rights for which the record date is prior to
the date such stock certificate is actually issued, except as otherwise provided
in Paragraph 12 hereof.
 

 

	
             
 	
            d)
 	
            The shares of Company common stock to be delivered to a Participant pursuant to the exercise of an option under the Plan will be registered in the name of the Participant or, if the Participant so directs by written notice to the Committee prior to the termination date of that phase of the Plan, in the names of the participant and one other person the Participant may designate as his or her joint tenant with rights of survivorship, to the extent permitted by law.
 

 

	
            11.
 	
            Accounting and Use of Funds.   Payroll deductions for each participant shall be credited to an account established for him or her under the Plan. A Participant may not make any separate cash payments into such account. Such account shall be solely for bookkeeping purposes and no separate fund or trust shall be established hereunder and the Company shall not be obligated to segregate such funds. All funds from payroll deductions received or held by the Company under the Plan may be used, without limitation, for any corporate purpose by the Company.
 

 

	
            12.
 	
            Adjustment Provision. 
 

 

	
             
 	
            a)
 	
            Subject to any required action by the shareholders of the Company, the number of shares covered by each outstanding option, and the price per share thereof in each such option, shall be proportionately adjusted for any increase or decrease in the number of issued shares of the Company common stock resulting from a subdivision or consolidation of shares or the payment of a share dividend (but only on the shares) or any other increase or decrease in the number of such shares effected without receipt of consideration by the Company. Except as otherwise provided in this preceding sentence, the Committee, in its sole discretion, may adjust the number or price of shares subject to the option by reason of any other dissolution, liquidation, merger, consolidation or spin-off of assets or stock of another corporation or the issuance of shares of any class, or securities
convertible into shares of any class of the Company.
 

 

	
             
 	
            b)
 	
            Effective beginning July 1, 2006, the Board of Directors may elect to accelerate the termination date of any Phase effective on the date specified by the Board of Directors in the event of (i) any consolidation or merger of the Company in which the Company is not the continuing or surviving corporation or pursuant to which shares of Stock would be converted into cash, securities or other property, other than a merger of the Company in which shareholders immediately prior to the merger have the same proportionate ownership of stock in the surviving corporation immediately after the merger; or (ii) any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company. Subject to any required action by the shareholders, if the Company shall be involved in any merger or
consolidation, in which it is not the surviving corporation, and if the Board of Directors does not accelerate the termination date of the Phase, each outstanding option shall pertain to and apply to the securities or other rights to which a holder of the number of shares subject to the option would have been entitled.
 

 

	
             
 	
            c)
 	
            A dissolution or liquidation of the Company shall cause each outstanding option to terminate, provided in such event that, immediately prior to such dissolution or liquidation, each Participant shall be repaid the payroll deductions credited to the Participant’s account without interest.
 

 

	
             
 	
            d)
 	
            In the event of a change in the shares of the Company as presently constituted, which is limited to a change of all its authorized shares with par value into the same number of shares with a different par value or without par value, the shares resulting from any such change shall be deemed to be the shares within the meaning of this Plan.
 

 

	
            13.
 	
            Non-Transferability of Options. 
 

 

	
             
 	
            a)
 	
            Options granted under any phase of the Plan shall not be transferable except under the laws of descent and distribution and shall be exercisable only by the Participant during his or her lifetime and after his or her death only by his or her beneficiary of the representative of his or her estate as provided in Paragraph 9(b) hereof.
 

4

	
             
 	
            b)
 	
            Neither payroll deductions credited to a Participant’s account, nor any rights with regard to the exercise of an option or to receive common stock under any phase of the Plan may be assigned, transferred, pledged or otherwise disposed of in any way by the Participant. Any such attempted assignment, transfer, pledge or other disposition shall be null and void and without effect, except that the Company may, at its option, treat such act as an election to withdraw funds in accordance with Paragraph 9.
 

 

	
            14.
 	
            
Designation of Beneficiary.   A Participant
may file a written designation of a beneficiary who is to receive any cash to
the Participant’s credit under any phase of the Plan in the event of such
Participant’s death prior to exercise of his or her option pursuant to
Paragraph 9(b) hereof, or to exercise his or her option and become entitled to
any stock and/or cash upon such exercise in the event of the Participant’s
death prior to exercise of the option pursuant to Paragraph 9(b) hereof. The
beneficiary designation may be changed by the Participant at any time by written
notice to the Company.

 

 

Upon the death of a Participant and upon receipt by the Company of proof deemed adequate by it of the identity and existence at the Participant’s death of a beneficiary validly designated under the Plan, the Company shall in the event of the Participant’s death under the circumstances described in Paragraph 9(b) hereof, allow such beneficiary to exercise the Participant’s option pursuant to Paragraph 9(b) if such beneficiary is living on the termination date of the phase and deliver to such beneficiary the appropriate stock and/or cash after exercise of the option. In the event there is no validly designated beneficiary under the Plan who is living at the time of the Participant’s death under the circumstances described in Paragraph 9(b) or in the event the option lapses, the Company shall deliver the cash credited to the account of the Participant without interest to
the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed to the knowledge of the Company, it may, in its discretion, deliver such cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. The Company will not be responsible for or be required to give effect to the disposition of any cash or stock or the exercise of any option in accordance with any will or other testamentary disposition made by such Participant or in accordance with the provision of any law concerning intestacy, or otherwise. No designated beneficiary shall, prior to the death of a Participant by whom he or she has been designated, acquire any interest in any stock or in any option or in the cash credited to the participant under any phase of the Plan.

 

	
            15.
 	
            Amendment and Termination.   The Plan may be terminated at any time by the Board of Directors provided that, except as permitted in Paragraph 12 hereof, no such termination will take effect with respect to any options then outstanding. Also, the Board may, from time to time, amend the Plan as it may deem proper and in the best interests of the Company or as may be necessary to comply with Section 423 of the Internal Revenue Code of 1986, as amended, or other applicable laws or regulations; provided, however, that no such amendment shall, without prior approval of the shareholders of the Company (1) increase the total number of shares for which options may be granted under the Plan (except as provided in paragraph 12 herein), (2) permit aggregate payroll deductions in excess of ten percent (10%) of a Participant’s compensation as of
the Commencement Date of a phase, or (3) impair any outstanding option.
 

 

	
            16.
 	
            Interest.   The Plan does not provide for the payment of interest on a Participant’s payroll deductions.
 

 

	
            17.
 	
            Notices.   All notices or other communications in connection with the Plan or any phase thereof shall be in the form specified by the Committee and shall be deemed to have been duly given when received by the Participant or his designated personal representative or beneficiary or by the Company or its designated representative, as the case may be.
 

 

	
            18.
 	
            Participation of Subsidiaries.   The Board of Directors may, by written resolution, authorize the employees of any of its subsidiaries to participate hereunder. Effective as of the date of coverage of any such subsidiary, any references herein to the “Company” shall be interpreted as referring to such subsidiary as well as to CNS, Inc. For purposes of this Plan, “Subsidiary” shall include any corporation defined as a subsidiary of the Company in Section 425(f) of the Internal Revenue Code of 1986, as amended. In the event that any subsidiary that is covered under the Plan ceases to be a subsidiary of CNS, Inc., the employees of such subsidiary shall be considered to have terminated their employment for purposes of Paragraph 9 hereof as of the date such subsidiary ceases to be such a subsidiary.
 

 

Adopted by Board of Directors:  January 27, 1989

Ratified and approved by shareholders:  April 26, 1989

Extension and amendment adopted by Board of Directors: July 15, 1999

Amendment adopted by Board of Directors   May 1, 2006

5<PAGE>

                                                                    EXHIBIT 4.11

AURAMET

                                                  AURAMET TRADING, LLC
                                                  2 Executive Drive, Suite 645
                                                  Fort Lee, NJ 07024
                                                  Phone: 201-905-5000
                                                  Fax: 201-905-5001
                                                  E-mail: jsullivan @auramet.com

                             COPPER, SILVER AND GOLD
                               PURCHASE AGREEMENT

     This COPPER, SILVER AND GOLD PURCHASE AGREEMENT (the "Agreement") dated as
of October 8, 2004 between MESTON RESOURCES INC., a corporation organized and
existing under the laws of Quebec, having an address at 1155 University Street,
Suite 1405, Montreal, Quebec H3B 3A7 (hereinafter referred to as "Meston"),
CAMPBELL RESOURCES, INC., a corporation organized and existing under the laws of
Quebec, having an address at 1155 University Street, Suite 1405, Montreal,
Quebec H3B 3A7 (hereinafter referred to as "Campbell") and AURAMET TRADING, LLC,
a Delaware limited liability company, having an address at 2 Executive Drive,
Suite 645, Fort Lee, New Jersey, 07024 (hereinafter referred to as "Auramet").

     WHEREAS, Meston owns and operates the Joe Mann Mine in Quebec (the "Mine"),
which produces a copper, silver and gold concentrate (the "Concentrates");

     WHEREAS, Campbell is the 100% owner of Meston;

     WHEREAS, Meston previously entered into a Refining Contract dated as of May
9, 2002 (the "Noranda Agreement"), with Noranda, Inc. (a company organized and
existing under the laws of Ontario), 181 Bay Street, Suite 4100, BCE Place,
Toronto, ON, Canada M5j 2T3 (hereinafter referred to as "Noranda"), a copy of
which is attached hereto as Exhibit A and incorporated herein by reference;
WHEREAS, pursuant to the terms of the Noranda Agreement, Meston has agreed to
sell and Noranda has agreed to receive, refine and purchase the Concentrates
upon the terms and conditions set forth in the Noranda Agreement.

     WHEREAS, Meston desires to obtain payment for the copper, silver and gold
contained in the Concentrates as the Concentrates are produced and shipped and
has requested that Auramet purchase such Concentrates pending their further sale
to Noranda under the Noranda Agreement, and Auramet is willing to so purchase
such Concentrates, up to the sum of Eight Million United States Dollars
($8,000,000) minus any sums that have been advanced under that certain Copper,
Silver and Gold Purchase Agreement (the "CCR Agreement") by and between Auramet
and Copper Rand Corporation Inc. of even date herwith the ("Facility Limit") on
the terms and conditions set forth herein;

     NOW THEREFORE, Meston and Auramet, for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, hereby agree as
follows:

<PAGE>

     Definitions:

     "Assignment Agreement" shall mean that certain Assignment Agreement from
Meston to Auramet dated as of October 8, 2004, acknowledged and agreed to by
Noranda, relating to the Noranda Agreement, substantially in the form of Exhibit
B hereto.

     "Dollars" and "U.S. $" means the lawful currency of the United States of
America.

     "Financing Period" shall mean the period between the Value Date (as defined
in Section 2(a)) and the Outturn Date.

     "Interest" shall mean LIBOR for the relevant Financing Period plus a spread
of 2.50% per annum.

     "LIBOR" shall mean the London Interbank Offer Rate for a duration closest
to the duration of the relevant Financing Period, as agreed between Auramet and
Meston.

     "Outturn Date" shall mean the date on which Noranda credits Auramet's
segregated metal account with the refined metal purchased by Auramet hereunder.

     All capitalized terms used herein and not otherwise defined shall have the
meanings ascribed thereto in the Noranda Agreement.

1. PURCHASE FACILITY

     Auramet shall make available to Meston a Purchase Facility (the "Purchase
Facility") of up to U.S. $8,000,000 (Eight Million Dollars) against delivery of
Concentrates under this Agreement, provided that all conditions precedent set
forth in Section 6 of this Agreement have been satisfied. Disbursement of the
Purchase Facility (each such disbursement being referred to herein as a
"Payment") shall be effected in installments corresponding to the shipment of
the Concentrates, each Payment to be made within two (2) Business Days after
satisfaction of such conditions precedent applicable to each such shipment as
set forth in Section 12.

2. PAYMENT CALCULATION

     The amount of each Payment with respect to Concentrates shipped shall be
calculated in accordance with the following procedure:

     On any day when Meston requests a Payment (the "Trade Date"), Auramet and
Meston shall confirm the following:

     a.   the date on which the trade shall be effective and the Payment shall
          be made (the "Value Date");

     b.   the Outturn Dates applicable to the copper, silver and gold for which
          the Payment is to be made;

                                       -2-

<PAGE>

     c.   the mid-point of the applicable Quotational Periods under the Noranda
          Agreement;

     d.   the applicable market based copper, gold or silver price; and

     e.   the applicable Interest.

     Meston shall submit to Auramet a Payment Request with respect to each
Payment in substantially the form of Exhibit C attached hereto (the "Payment
Request").

               (i) The Payment Request shall take items a-d above, as confirmed
          pursuant to the foregoing, to produce a forward price per pound of
          copper, and per ounce of gold and silver said to be contained in the
          Concentrates as to which Payment is sought (the "Forward Price");

               (ii) The Forward Price shall be applied to the net payable (after
          deductions taken by Noranda pursuant to and in accordance with the
          Noranda Agreement) quantity of copper, gold and silver said to be
          contained in the Concentrates as to which Payment is sought, and the
          estimated treatment charges, refining charges and penalties to be
          imposed by Noranda and the Base Copper Price Participation
          (collectively, the "Noranda Charges") shall be deducted therefrom,
          thereby producing a net price for such Concentrates (the "Net Price");

               (iii) The Net Price for the copper and silver shall be multiplied
          by 90%, and the gold by 100%, up to the total Facility Limit of this
          Purchase Facility (the "Payment Ratio"); and

               (iv) The estimated Interest applicable to the Financing Period
          for such Payment shall be deducted from the result of the foregoing to
          produce the amount of the disbursement to be made to Meston.

     Notwithstanding the Quotational Periods set forth in the Noranda Agreement,
for purposes of this Agreement pricing shall be determined as set forth herein.
Meston and Auramet agree that (i) with respect to all Concentrates priced by
Auramet pursuant to this Payment Facility, Auramet shall bear all market price
fluctuation risk associated with such Concentrates; (ii) with respect to all
Concentrates unpriced pursuant to this Payment Facility, Meston shall bear all
market price fluctuation risk associated with such Concentrates; and (iii)
Meston shall be under no obligation to request pricing and corresponding payment
advances hereunder.

3. SETTLEMENT; SECURITY

     Auramet will provide Seller with a Monthly Outturn Report which shall
include the details of all pricings, outturns, payments, and adjustments. This
shall be an perpetual electronic file which will be used by Seller and Buyer to
monitor movements in the over/under account.

                                       -3-

<PAGE>

     Notwithstanding the foregoing, (i) on each Outturn Date, Meston and Auramet
shall adjust the amount then due and owing to Auramet to reflect the correct
Interest based on the actual Reimbursement Date; and (ii) on the date of each
provisional final and final payment made by Noranda, Auramet and Meston shall
adjust their corresponding trades with respect to the subject Concentrates to
establish the amount due to or owed by Auramet based upon the final pricing of
such Concentrates under the Noranda Agreement, and the parties shall promptly
settle such amount. An example of such settlement is attached hereto as Exhibit
D.

     Notwithstanding the foregoing, Meston and Auramet agree that no payment
shall be made by Auramet hereunder after December 31, 2005 (the "Termination
Date") and that all amounts that remain outstanding hereunder on April 15, 2006,
shall be immediately reimbursed by Meston to Auramet (the "Final Repayment
Date"). Auramet may on thirty (30) calendar days prior notice to Meston, extend
the Termination Date and Final Repayment Date for two (2) successive periods of
one year.

     In order to guarantee and secure compliance with each one of the
obligations of Meston contained herein, Meston hereby agrees as follows:

     a.   Meston hereby agrees not to create or execute contracts with the
          obligation to sell, impose liens, alienate, promise to sell, pledge,
          grant an option, celebrate acts or execute contracts of any nature
          related to the Concentrates produced and/or purchased by Meston and
          covered by this Agreement;

     b.   The contracts entered into with respect to the Forward Prices
          determined in Section 2 above shall be subject to the terms set forth
          in that certain Trading Agreement, dated as of October 8, 2004 among
          Meston and Auramet (the "Trading Agreement"); and

     c.   In addition to, and not in derogation of, the Trading Agreement,
          Meston hereby pledges, assigns and grants a security interest in, over
          and to all futures, forwards, contracts, options, puts, calls and
          currency trades of any kind entered into by and between Meston and
          Auramet.

4. SHORTFALLS

     Notwithstanding any of the foregoing, in the event, for any reason, that
there is a shortfall at Outturn, such that the Buyer's Metal Account is not
credited with the Estimated Quantity, or there is less metal for sale to Noranda
than Buyer purchased from Seller, Seller shall immediately, through pool
transfer, market transaction, or other manner acceptable to Buyer, transfer to
Buyer's Metal Account the subject PM shortfall.

     In the event that there is a surplus at Outturn, such that Buyer's Metal
Account is credited with more than the Estimated Quantity, then Seller may elect
to immediately sell the surplus amount at Buyer's then current spot market
price, or maintain the surplus balance of ounces in its account with Buyer until
sold on a date specified by Seller in the future.

                                       -4-

<PAGE>

     For practical purposes, with respect to the gold purchased hereunder,
Seller and Buyer may mutually agree to keep an ongoing over/under account which
is to be settled whenever the over/under market value of gold exceeds $100,000
U.S Dollars.

5. TAXES

     All sums payable by Meston hereunder, whether reimbursement of the
Payments, interest, commission or otherwise, shall be paid in full, without
set-off, deduction or counterclaim and free and clear of and without any
deduction of or withholding for or on account of any taxes or any restrictions
or conditions of any nature, unless Meston is required by the law to make such
deduction or withholding. If Meston is required by law to make any such
deduction or withholding, then Meston shall ensure that such deduction or
withholding will not exceed the minimum legal liability therefore and shall
simultaneously pay to Auramet such additional amount as will result in the
receipt by Auramet of a net amount equal to the full amount which would
otherwise have been receivable hereunder had no such deduction or withholding
been required. If Meston shall make such deduction or withholding, Meston shall
within 30 calendar days thereafter forward to Auramet an official receipt or
other official documentation evidencing the payment of the deduction or
withholding.

6. CONDITIONS PRECEDENT

     Prior to the disbursement of the first Payment, Meston shall submit to
Auramet the following documents:

     a.   This Agreement duly signed and executed.

     b.   The Noranda Agreement duly signed and executed.

     c.   The Assignment Agreement, duly signed and executed.

     d.   The Guaranty of Campbell, guaranteeing all obligations of Meston to
          Auramet substantially in the form of Exhibit E hereto (the
          "Guaranty").

     e.   A Certificate from the Corporate Secretary of Meston, certifying (i)
          Meston's corporate charter, (ii) a Board of Directors resolution
          authorizing the transactions contemplated hereby, and (iii) the
          authority of Meston's authorized representatives to sign and commit on
          behalf of Meston.

     f.   A Certificate of Insurance from Noranda with respect to the
          Concentrates at all times while this Agreement is in effect

     g.   A copy of the Trading Agreement, duly signed and executed.

     Prior to the disbursement of the first and each subsequent Payment, Meston
shall deliver to Auramet the following documents:

     h.   The Assay Reports issued based upon samples taken at Meston for the
          subject Concentrates, substantially in the form attached hereto as
          Exhibit F;

                                       -5-

<PAGE>

     i.   The Recu de Material a Facon/Receipt of Custom Material and the
          Rapport De La Preparation Des Concentres/Concentrate Preparation
          Report, issued by Noranda and countersigned by an independent
          representative retained for that purpose, in substantially in the form
          of Exhibit G hereto

     j.   A duly executed Payment Request.

     k.   Such other documentation as Auramet shall reasonably require (none
          contemplated at this time).

In addition, Meston shall request the assays prepared on Noranda's behalf as
soon as practical following the taking of samples with respect to the
Concentrates at Noranda and shall direct that copies of the same be sent to
Auramet simultaneously with their delivery to Meston.. Auramet may, at any time,
request that independent assays be performed and may nominate any such assayer
to perform such assays, the cost of any such assays to be borne by Meston if
such assays are ordered based on some reasonable concern raised by Auramet, and
in the absence of such concern, such costs shall be allocated as shall be agreed
by the parties at the time. In addition to the foregoing documentary
requirements, it shall be a condition precedent to any Payment hereunder that
there shall have occurred no Event of Default, or condition which with notice or
the passage of time or both would become an Event of Default and all
representations and warranties set forth herein shall be true and correct.

7. REPRESENTATIONS AND WARRANTIES

     Meston represents and warrants as follows:

     a.   Meston has full power, authority and legal right to execute and
          deliver this Agreement, the Trading Agreement, the Assignment
          Agreement and the Noranda Agreement and to perform its obligations
          hereunder and thereunder, and to receive the Payment, and this
          Agreement, the Trading Agreement, the Assignment Agreement and the
          Noranda Agreement constitute Meston's valid and binding obligations
          enforceable against Meston in accordance with their terms. Meston has
          obtained all corporate approvals and authorizations necessary in
          connection with its execution, delivery and performance of this
          Agreement, the Trading Agreement, the Assignment Agreement and the
          Noranda Agreement;

     b.   Meston has obtained all necessary governmental, local authority or
          agency approvals, quotas, licenses, permits, and authorizations to
          fully enable it to enter into this Agreement, the Trading Agreement,
          the Assignment Agreement and the Noranda Agreement and to make
          repayment in cash dollars if necessary under the terms and conditions
          of this Agreement;

     c.   Meston's execution and delivery of this Agreement, the Trading
          Agreement, the Assignment Agreement and the Noranda Agreement and
          Meston's performance of its obligations hereunder and thereunder, do
          not and will not violate Meston's governing corporate instruments nor
          any indenture, agreement, loan agreement, note, restriction,
          obligation or liability by which Meston or Campbell is bound or to
          which it or any of its assets are subject;

                                       -6-

<PAGE>

     d.   There are no pending or threatened actions or proceedings before any
          court or administrative agency, which may materially and adversely
          affect Meston's financial ability to fulfill its obligations under
          this Agreement, the Trading Agreement, the Assignment Agreement and
          the Noranda Agreement;

     e.   Meston is a corporate body duly constituted and validity existing as
          an independent legal entity under the laws of Quebec and is fully
          qualified and empowered to own its assets and carry on its operations
          and activities as now conducted;

     f.   Neither Meston nor its assets enjoys, under the laws of Quebec or any
          other legal system or jurisdiction, any right of immunity from suit,
          judgment set-off, execution on a judgment, attachment or other legal
          process in respect of any of Meston's obligations under this
          Agreement, the Trading Agreement, the Assignment Agreement and Noranda
          Agreement;

     g.   All of the obligations of Meston under this Agreement, the Trading
          Agreement, the Assignment Agreement and the Noranda Agreement are
          direct, unconditional and general obligations of Meston and rank and
          will rank at least pari passu in all respect with other present of
          future obligations and liabilities (including contingent obligations
          and liabilities) of Meston;

     h.   Meston's execution and delivery of this Agreement, the Trading
          Agreement, the Assignment Agreement and the Noranda Agreement and
          Meston's performance obligations hereunder and thereunder do not and
          will not contravene any provision of any law, decree, regulation,
          rule, directive or similar enactment or any structural adjustment
          program by which Meston or any of its assets is bound or cause any
          limit on any of the powers of Meston (whether imposed by law, decree,
          regulation, agreement or otherwise) or on the right or ability of its
          officers to exercise such powers or any other limits affecting Meston
          to exceeded;

     i.   No Event of Default as specified in Section 9 below has occurred and
          is continuing;

     j.   No information, exhibit documents or report furnished in writing by
          Meston or Auramet or provided by Auramet and approved by Meston in
          connection with negotiation of this Agreement, the Trading Agreement,
          the Assignment Agreement or the Noranda Agreement contained any
          mis-statement of fact as at the date of such exhibit, document or
          report or as at the date when such information was given, or omitted
          to state a fact as at such date which in any such case would be of
          material interest to a person deciding whether to enter into or
          otherwise participate in this Agreement, the Trading Agreement, the
          Assignment Agreement or the Noranda Agreement;

     k.   There are no encumbrances of any nature affecting the Concentrates to
          be delivered hereunder and under the Noranda Agreement;

                                       -7-

<PAGE>

     l.   All sums owing by Meston under the Noranda Agreement have been paid in
          full in accordance with the terms of the Noranda Agreement; the
          Noranda Agreement is in full force and effect and there are no
          disputes or claims thereunder by either side, nor has any suspension
          of performance or force majeure been declared by either party thereto;

     m.   Meston has no subsidiaries, other than Meston Investments, Inc., a
          Cayman Islands corporation.

     The representations and warranties contained in this Section 7 are given by
Meston as at the date hereof and throughout the period during which this
Agreement is in force, and are specifically made and reaffirmed without any
additional act or document by issuance of a Payment Request by Meston and by the
acceptance by Meston of each Payment thereunder.

8. COVENANTS AND UNDERTAKINGS

Meston covenants and undertakes that:

     a.   It will duly and promptly perform and observe all of its obligations
          under this Agreement, the Trading Agreement, the Assignment Agreement
          and the Noranda Agreement, including, but without limitation, all its
          obligations in relation to the delivery of Concentrates hereunder and
          under the Noranda Agreement.

     b.   It shall promptly notify Auramet of the occurrence of any event that:

               (i) constitutes, or that after notice, lapse of time or both
          would constitute, an event of default as stipulated herein, or

               (ii) would reasonably be expected to have a material adverse
          impact on Meston's financial position or the result of its operation
          or its general business operations.

     c.   It will furnish to Auramet:

               (i) as soon as practicably available, all assays issued with
          respect to the Concentrates;

               (ii) as soon as practicably available, all Receiving Reports in
          form and content acceptable to Auramet, for all Concentrates;

               (iii) prompt notification of the shipment of the Concentrates;
          and

     d.   Unless otherwise agreed in writing by Meston and Auramet, it will not
          sell or deliver the Concentrates to any party other than Auramet for
          further sale and delivery to Noranda; nor will it create or permit to
          subsist any encumbrance over or affecting the Concentrates to be
          delivered pursuant hereto or to the Noranda Agreement or create or
          permit to subsist any encumbrance over or affecting the whole or any
          of its undertaking, revenue, charges or other assets, present or

                                       -8-

<PAGE>

          future, which encumbrance may affect the obligations of Meston under
          this Agreement, the Assignment Agreement or the Noranda Agreement, or
          the ability of Auramet to enforce its rights hereunder or thereunder,
          or pursuant to any court order or judgment in respect hereof, against
          Meston.

     e.   Meston will at all times obtain or effect and maintain in effect and
          comply with all the terms and conditions of all legislative,
          governmental and other authorizations, approvals, licenses, permits,
          registrations and consents necessary or appropriate for execution or
          delivery of this Agreement, the Assignment Agreement and the Noranda
          Agreement, or the utilization of the Payment Facility, or to render
          this Agreement, the Assignment Agreement and the Noranda Agreement
          legal, valid, binding and admissible in evidence.

     f.   Meston will comply with the requirements of all laws, decrees,
          regulations, orders and rules of any administrative or governmental
          authority or organization applicable to its activities and operations
          and will do all things necessary to preserve and keep in full force
          and effect all material franchises, concessions, licenses or permits
          to which it is presently entitled.

     g.   Meston will not alter, amend, modify, rescind or waive any provision
          of the Noranda Agreement or the Assignment Agreement without Auramet's
          prior written consent.

9. EVENTS OF DEFAULT

     An Event of Default will occur if:

     a.   Any metal is not outturned on the Outturn Date applicable thereto or
          Meston or Campbell fails to pay any other sum payable by it hereunder,
          or deliver any amount of metal to be delivered hereunder, or under the
          Trading Agreement, the Noranda Agreement, the Assignment Agreement or
          the Guaranty or under any agreement with Auramet at the time, in the
          currency and otherwise in the manner specified herein or therein;

     b.   Any formal action is taken to wind up, liquidate, place into
          administration or dissolve Meston or Campbell whether voluntarily or
          by any third party;

     c.   Any representation, warranty, covenant or undertaking made by Meston
          or Campbell in this Agreement, the CCR Agreement, the Trading
          Agreement, the Noranda Agreement, the Assignment Agreement or the
          Guaranty shall prove to be at any time incorrect or misleading in any
          material aspect;

     d.   Meston or Campbell defaults in the performance of any term covenant or
          obligation contained in this Agreement, the Trading Agreement, the
          Noranda Agreement, the Assignment Agreement or the Guaranty or under
          any other agreement with Auramet, including but note limited to the
          Trading Agreement, and fails to remedy such default, if capable of
          remedy in the opinion of Auramet, within 30 calendar days after
          receipt of notice by Auramet.

                                       -9-

<PAGE>

     e.   Meston or Campbell becomes insolvent, bankrupt or ceases paying its
          debts as they become due, or a trustee, receiver or liquidator is
          appointed or bankruptcy or similar proceedings are instituted against
          Meston or Campbell under the laws of any jurisdiction;

     f.   An Event of Force Majeure as defined in the Noranda Agreement occurs
          and such event lasts for longer than 60 days;

     g.   It becomes unlawful or impossible for Meston or Campbell to perform
          any of its remaining obligations in terms of the Noranda Agreement,
          this Agreement, the Trading Agreement, the Assignment Agreement or the
          Guaranty;

     h.   Meston or Campbell suspends payment of its debts or proposes to or
          enters into any composition or arrangement or the benefit of creditor
          (or any of them) or begins negotiations or takes any steps with a view
          to any steps with a view to any readjustment, rescheduling or deferral
          of Meston's or Campbell's indebtedness (or a material part thereof);

     i.   A deterioration occurs in the financial condition of Meston and
          Campbell, taken as a whole, which in the reasonable opinion of Auramet
          is likely to have a material adverse effect on Meston to perform its
          obligations under this Agreement and/or the Noranda Agreement or on
          Campbell and the Guaranty;

     j.   There is a change of ownership of Meston during the term of this
          Agreement, for which Meston or Campbell has not obtained Auramet's
          prior written consent, which consent shall not be unreasonably
          withheld;

     k.   Any order or declaration is made or judgment given by any court or
          authority the effect of which is to enjoin or restrain the performance
          or observance by Meston of the terms of this Agreement, the Noranda
          Agreement or the Assignment Agreement or in any manner restrict the
          right and power of Meston or Campbell to enter into, exercise its
          rights under and perform and observe the terms of this Agreement or
          the Noranda Agreement or the Assignment Agreement or the Guaranty or
          affect the legality, validity, enforceability or binding nature
          thereof;

     l.   It becomes or proves to be unlawful or impossible for Meston or
          Campbell duly and promptly to perform or observe any of its
          obligations or undertakings in this Agreement or the Noranda Agreement
          or the Assignment Agreement or the Guaranty or for any other reason
          whatsoever this Agreement or the Noranda Agreement or the Assignment
          Agreement or the Guaranty ceases to be in full force or effect; or

     m.   if Meston and/or Campbell suffers a material adverse change in its
          financial and/or economic condition or status, which change may have a
          material adverse effect on the enforceability of any terms of this
          Agreement, the Trading Agreement, the Assignment Agreement, or the
          Guaranty or the ability of Meston and/or Campbell to fulfill their
          obligations hereunder or thereunder as reasonably and fairly
          determined by Auramet or its financial advisors.

                                      -10-

<PAGE>

     Upon the occurrence of any of the Events of Default described in this
Section 9, Auramet shall have the following rights:

     a.   To terminate the performance of any or all of its obligations under
          this Agreement to Meston and Campbell;

     b.   To demand to receive immediate payment of all amounts outstanding
          hereunder;

     c.   To demand payment from Meston of all recoverable losses and other
          damages including reasonable legal fees and expenses incurred in the
          exercise of the foregoing and any other remedies, but not in
          duplication of Section 12;

     d.   To set-off against any and all accounts, credits or balances
          maintained by them when the same shall be due and payable, including
          any balances under the Noranda Agreement, whether at maturity upon
          acceleration or otherwise;

     e.

     f.   To further exercise any other rights, powers, privileges and remedies
          available to it under this Agreement at law or in equity, any and all
          of which may be exercised by Auramet at any time and from time to
          time, whether or not Auramet shall have instituted any proceedings or
          other action for the enforcement of its rights hereunder or any of the
          documents in connection herewith; and/or

     g.   To claim against Campbell as provided in the Guarantee.

     No waiver by a party of any breach of the Agreement by the other party
     shall be considered as a waiver of any subsequent breach of the same or any
     provision of this Agreement.

10. NOTICES

     Notices hereunder shall be deemed to have been given when sent by cable,
telex or telefax in each case addressed to any party as follows:

<TABLE>
<S>                      <C>
Auramet Trading, LLC     To the address set forth in the preamble hereto with a
                         copy to:

                         Auramet Trading, LLC
                         Fax: (201) 905-5001 and via e-mail to

                         jsullivan@auramet.com

Meston Resources, inc.   At the address set forth in the preamble hereto with a
                         copy to:
</TABLE>

                                      -11-

<PAGE>

                                        Campbell Resources, Inc.
                                        Fax: (514) 875-9764 and via e-mail to
                                        lbrun@campbellresources.com

11. COST; INDEMNIFICATION

     All and any costs (including, but without limitation, legal fees and
expenses and any value added tax), costs of collection, court fees, assayer
fees, travel expenses, stamp and other duties and taxes incidental to this
Agreement (other than taxes on Auramet's income generally), whether payable as a
result of any default or documentation, certificate, authorizations, permits,
quotas, permissions, registrations incurred by Auramet related to this Payment
Facility shall be paid by Meston. Meston shall indemnify and hold harmless
Auramet from and against all claims, demands, costs, expenses (including
reasonable attorney's fees) as may be incurred by Auramet as well as from and
against all liabilities, and losses arising from or related to this Agreement,
the Payment Facility and the delivery, acceptance and shipment of the
Concentrates, including, without limitation, any environmental, maritime, tax,
local, regional, national, political or civil dispute, or otherwise.

12. OTHER CONDITIONS

     a.   Auramet shall not assign or dispose of any or all its interest in this
          Agreement or the Noranda Agreement without the prior approval of
          Meston, provided that Auramet may assign the same for financing
          purposes. Meston shall not be entitled to assign or dispose of any or
          all of its interest in this Agreement or the Noranda Agreement.

     b.   All payments by Meston shall be made in Dollars free and clear of any
          deduction or withholding tax on account of any tax imposed, levied,
          collected, withheld or assessed by Canada, Quebec or any other
          country/government.

                                      -12-

<PAGE>

13. JURISDICTION

     Meston hereby appoints Andre Fortier, Chief Executive Officer of Campbell
to receive, for it and on its behalf service of process in any proceedings in
the United States. Meston and Campbell hereby consent to the jurisdiction of all
state and local courts of the State of New York and of the United States of
America for the Southern District of New York or, at the option of Auramet, any
court in which Auramet decides to initiate legal or equitable proceedings
concerning the Guaranty, the finance documents or any other matters related
thereto in which the court has subject matter jurisdiction over the matter and
controversy; and to the extent permitted by law, Meston and Campbell hereby
waive judicial service of the summons and complaint or other process of the
papers issued therein and agree that service may be made by registered or
certified mail addressed to Meston and to Campbell at their respective notice
address set forth herein.

Accepted for and on behalf of:

MESTON RESOURCES INC.

By: /s/ A.Y. FORTIER
    ---------------------------------
Name: A.Y. FORTIER
Title: PRESIDENT

By:
    ---------------------------------
Name:
      -------------------------------
Title:
       ------------------------------

AURAMET TRADING, LLC.

By: /s/ Justin M. Sullivan
    ---------------------------------
Name: Justin M. Sullivan
Title: COO

GUARANTOR:

CAMPBELL RESOURCES, INC.

By: /s/ A.Y. Fortier
    ---------------------------------
Name: A.Y. FORTIER
Title: PRES. & CEO
Date:
      -------------------------------

                                      -13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]